drugset / Trial / NCT00960063
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in conformance with Good Clinical Practices. This study will evaluate the safety, tolerability and dose-finding of robatumumab when administered in combination with temozolomide and irinotecan (Arm A); or cyclophosphamide, doxorubicin, and vincristine (Arm B), or ifosfamide and etoposide (Arm C). The primary study hypothesis is that robatumumab can be safely administered in combination with chemotherapy regimens in pediatric participants with solid tumors.
Timeline
- Start
- 2009-11-11
- Primary completion
- 2010-12-22
- Completion
- 2010-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Robatumumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Robatumumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 1200 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 1800 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 10 mg/m2 | Intravenous |
| Background | Temozolomide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 2 mg/m2 | Intravenous |